Sign In
Buy ALTO
$5.65
-0.0100 (-0.177%)
At Close: Jun 11, 2026
Alto Ingredients (ALTO) Q3 Earnings and Revenues Surpass Estimates
07:51pm, Wednesday, 05'th Nov 2025
Alto Ingredients (ALTO) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to a loss of $0.04 per share a year ago.
Alto Ingredients, Inc. (ALTO) Q3 2025 Earnings Call Transcript
07:21pm, Wednesday, 05'th Nov 2025
Alto Ingredients, Inc. ( ALTO ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Bryon McGregor - CEO, President & Director Robert Olander - Chief Financial Officer Conference C
Alto Ingredients, Inc. to Release Third Quarter 2025 Financial Results on November 5, 2025
08:30am, Wednesday, 29'th Oct 2025
PEKIN, Ill., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO) a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced it w
Alto Ingredients (NASDAQ:ALTO) Trading 4.6% Higher – Here’s What Happened
02:38am, Tuesday, 21'st Oct 2025
Alto Ingredients, Inc. (NASDAQ: ALTO - Get Free Report) shares traded up 4.6% on Monday. The stock traded as high as $1.17 and last traded at $1.13. 319,720 shares traded hands during trading, a decli
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medic
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you are a long-term stoc
Alto Ingredients, Inc. to Present in the LD Micro Main Event XIX
08:30am, Tuesday, 07'th Oct 2025
PEKIN, Ill., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced tha
Alto Ingredients Applauds Passage of Assembly Bill 30 Expanding E15 Fuel Options in California
08:30am, Monday, 06'th Oct 2025
PEKIN, Ill., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, welcomes the
Alto Ingredients, Inc. to Present in the 27th Annual H.C. Wainwright Global Investment Conference
04:05pm, Tuesday, 02'nd Sep 2025
PEKIN, Ill., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced th
Victoria's Secret Has Opened Its New Flagship Store in Miami Beach, Marking a Bold New Chapter for the Iconic Brand
10:18am, Tuesday, 19'th Aug 2025
MIAMI--(BUSINESS WIRE)--ALTO Real Estate Funds announced the opening of Victoria's Secret's flagship store. After relocating from a nearby site, Victoria's Secret secured a 12-year lease with ALTO Rea
Alto Ingredients, Inc. (ALTO) Q2 2025 Earnings Call Transcript
09:21pm, Wednesday, 06'th Aug 2025
Alto Ingredients, Inc. (NASDAQ:ALTO ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bryon T. McGregor - CEO, President & Director Robert R.
Alto Ingredients (ALTO) Reports Q2 Loss, Beats Revenue Estimates
06:21pm, Wednesday, 06'th Aug 2025
Alto Ingredients (ALTO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.05 per share a year ago.
Alto Ingredients, Inc. Reports Second Quarter 2025 Results
04:05pm, Wednesday, 06'th Aug 2025
- Western Assets Increased Gross Profit by $5.6 Million, Compared to Q2 2024 - PEKIN, Ill., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel
